Mineralocorticoid Excess Syndrome, Apparent
Mineralocorticoids
11-beta-Hydroxysteroid Dehydrogenases
11-beta-Hydroxysteroid Dehydrogenase Type 2
Receptors, Mineralocorticoid
Hydroxysteroid Dehydrogenases
Aldosterone
Mineralocorticoid Receptor Antagonists
Cortisone
Desoxycorticosterone
Hypokalemia
Apparent mineralocorticoid excess syndrome: an overview. (1/12)
Apparent mineralocorticoid excess (AME) syndrome results from defective 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2). This enzyme is co-expressed with the mineralocorticoid receptor (MR) in the kidney and converts cortisol (F) to its inactive metabolite cortisone (E). Its deficiency allows the unmetabolized cortisol to bind to the MR inducing sodium retention, hypokalemia, suppression of PRA and hypertension. Mutations in the gene encoding 11beta-HSD2 account for the inherited form, but a similar clinical picture to AME occurs following the ingestion of bioflavonoids, licorice and carbenoxolone, which are competitive inhibitors of 11beta-HSD2. Reduced 11beta-HSD2 activity may explain the increased sodium retention in preeclampsia, renal disease and liver cirrhosis. Relative deficiency of 11beta-HSD2 activity can occur in Cushing's syndrome due to saturation of the enzyme and explains the mineralocorticoid excess state that characterizes ectopic ACTH syndrome. Reduced placental 11beta-HSD2 expression might explain the link between reduced birth weight and adult hypertension. Polymorphic variability in the HSD11B2 gene in part determines salt sensitivity, a forerunner for adult hypertension onset. AME represents a spectrum of mineralocorticoid hypertension with severity reflecting the underlying genetic defect in the 11beta-HSD2; although AME is a genetic disorder, several exogenous compounds can bring about the symptoms by inhibiting 11beta-HSD2 enzyme. Substrate excess as seen in Cushing's syndrome and ACTH ectopic production can overwhelm the capacity of 11beta-HSD2 to convert F to E, leading up to an acquired form of AME. (+info)Exogenously-induced apparent hypermineralocorticoidism associated with ingestion of "asam boi". (2/12)
A 31-year-old woman presented with a one-week history of headache, generalised lethargy, weakness and poor appetite. Clinical examination showed that her blood pressure was 200/120 mmHg. On an earlier occasion, her blood pressure was found to be normal by a general practitioner whom she last visited three months earlier when she had an upper respiratory tract infection. Investigations showed hypokalaemia, suppressed serum renin and aldosterone. Further history was taken and revealed that she had been craving for guava fruits which she ate with flavoured "asam boi" (containing glycyrrhizic acid) at least three spoonfuls twice a day for the past six weeks. The hypertension and hypokalaemia resolved after two weeks of stopping the "asam boi". Her clinical picture was compatible with exogenously-induced hypermineralocortoidism. (+info)The mother or the fetus? 11beta-hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids. (3/12)
Low birth weight associates with increased susceptibility to adult cardiometabolic and affective disorders spawning the notion of fetal "programming." Prenatal exposure to excess glucocorticoids may be causal. In support, maternal stress or treatment during pregnancy with dexamethasone (which crosses the placenta) or inhibitors of fetoplacental 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), the physiological "barrier" to maternal glucocorticoids, reduces birth weight and programs permanent offspring hypertension, hyperglycemia, and anxiety behaviors. It remains uncertain whether such effects are mediated indirectly via altered maternal function or directly on the fetus and its placenta. To dissect this critical issue, we mated 11beta-HSD2(+/-) mice such that each pregnant female produces +/+, +/-, and -/- offspring and compared them with offspring of homozygous wild-type and -/- matings. We show that 11beta-HSD2(-/-) offspring of either +/- or -/- mothers have lower birth weight and exhibit greater anxiety than 11beta-HSD2(+/+) littermates. This provides clear evidence for the key role of fetoplacental 11beta-HSD2 in prenatal glucocorticoid programming. (+info)Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. (4/12)
In mineralocorticoid target tissues such as the cortical collecting duct in the kidney, the enzyme 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) is responsible for the peripheral inactivation of cortisol to cortisone, thereby protecting the mineralocorticoid receptor from inappropriate activation by cortisol. Mutations in the HSD11B2 gene cause the syndrome of apparent mineralocorticoid excess, an autosomal recessive form of inherited hypertension in which cortisol acts as a potent mineralocorticoid. Herein are described six new families with mutations in the HSD11B2 gene causing hypokalemic hypertension, with low plasma aldosterone and low renin levels in affected individuals, indicating mineralocorticoid hypertension. Profiling of urinary steroid metabolites showed decreased cortisol inactivation, with urinary tetrahydrocortisol and tetrahydrocortisone ratio (THF + 5alphaTHF)/THE ranging 2.4 to 40 and nearly absent urinary free cortisone in all but one case. Genetic analysis of the HSD11B2 gene from these patients with apparent mineralocorticoid excess revealed distinct homozygous point mutations in four families, a compound heterozygous mutation in one family, and a large 23-bp exonic insert with frameshift and disruption of the amino acid sequence in another family. Expression studies of mutants that were expressed in HEK-293 cells showed marked reduction or abolition of 11betaHSD2 enzymatic activity. These cases are reviewed along with previous ones from the authors' extensive personal experience to highlight the importance of 11betaHSD2 in the understanding of a new biologic principle in hormone action, demonstrating that local metabolism of the glucocorticoid hormones into inactive derivatives by the enzyme 11betaHSD2 is one of the mechanisms that intervene to allow specific aldosterone regulatory effects. (+info)Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. (5/12)
Apparent mineralocorticoid excess (AME) is a severe form of hypertension that is caused by impaired activity of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2), which converts biologically active cortisol into inactive cortisone. Mutations in HSD11B2 result in cortisol-induced activation of mineralocorticoid receptors and cause hypertension with hypokalemia, metabolic alkalosis, and suppressed circulating renin and aldosterone concentrations. This study uncovered the first patient with AME who was described in the literature, identified the genetic defect in HSD11B2, and provided evidence for a novel mechanism of reduced 11beta-HSD2 activity. This study identified a cluster of amino acids (335 to 339) in the C-terminus of 11beta-HSD2 that are essential for protein stability. The cluster includes Tyr(338), which is mutated in the index patient, and Arg(335) and Arg(337), previously reported to be mutated in hypertensive patients. It was found that wild-type 11beta-HSD2 is a relatively stable enzyme with a half-life of 21 h, whereas that of Tyr(338)His and Arg(337)His was 3 and 4 h, respectively. Enzymatic activity of Tyr(338)His was partially retained at 26 degrees C or in the presence of the chemical chaperones glycerol and dexamethasone, indicating thermodynamic instability and misfolding. The results provide evidence that the degradation of both misfolded mutant Tyr(338)His and wild-type 11beta-HSD2 occurs through the proteasome pathway. Therefore, impaired 11beta-HSD2 protein stability rather than reduced gene expression or loss of catalytic activity seems to be responsible for the development of hypertension in some individuals with AME. (+info)Two elderly patients with mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD2) impairment. (6/12)
A 75-year-old woman had a low circulating level of aldosterone, despite the mineralocorticoid excess state. These abnormalities were improved by spironolactone administration. The distinct elevation of urinary cortisol/cortisone ratio revealed 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) impairment. Moreover, slight but distinct elevation of the ratio was found in a 95-year-old woman with normotension and normopotassemia. The mineralocorticoid excess state with reduced aldosterone level appeared following with vomiting and diarrhea, exaggerating asymptomatic impairment of 11beta-HSD2 to induce apparent mineralocorticoid excess (AME)-like condition. (+info)Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene. (7/12)
(+info)In silico structure-function analysis of pathological variation in the HSD11B2 gene sequence. (8/12)
(+info)Apparent Mineralocorticoid Excess Syndrome (AME) is a rare inherited endocrine disorder characterized by the overproduction of the mineralocorticoid hormone aldosterone or an increased sensitivity to aldosterone at the level of its target organs. This leads to an excessive reabsorption of sodium and water, as well as an increased excretion of potassium in the urine.
The term "apparent" is used because, despite elevated levels of aldosterone, the regulation of aldosterone secretion appears to be normal. In other words, the syndrome is not caused by a primary defect in the adrenal glands, but rather by an inherited mutation that affects the mineralocorticoid receptor or the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2).
The most common form of AME is caused by a mutation in the gene encoding 11β-HSD2, which is normally responsible for converting cortisol to cortisone in the kidney. Cortisol has a higher affinity for the mineralocorticoid receptor than aldosterone, but its effects are usually blocked by 11β-HSD2. In AME, however, the mutation in 11β-HSD2 leads to an accumulation of cortisol in the kidney, which can then bind to and activate the mineralocorticoid receptor, mimicking the effects of aldosterone.
The clinical features of AME include hypertension, hypokalemia (low potassium levels), metabolic alkalosis (an increase in blood pH due to loss of hydrogen ions in the urine), and suppressed plasma renin activity. If left untreated, AME can lead to severe complications such as heart failure, stroke, and kidney damage. Treatment typically involves the use of medications that block the mineralocorticoid receptor or inhibit aldosterone production.
Mineralocorticoids are a class of steroid hormones that primarily regulate electrolyte and fluid balance in the body. The most important mineralocorticoid is aldosterone, which is produced by the adrenal gland in response to signals from the renin-angiotensin system. Aldosterone acts on the distal tubules and collecting ducts of the nephrons in the kidneys to increase the reabsorption of sodium ions (Na+) and water into the bloodstream, while promoting the excretion of potassium ions (K+) and hydrogen ions (H+) into the urine. This helps maintain blood pressure and volume, as well as ensuring a proper balance of electrolytes in the body. Other mineralocorticoids include cortisol and corticosterone, which have weak mineralocorticoid activity and play a more significant role as glucocorticoids, regulating metabolism and immune response.
11-Beta-Hydroxysteroid dehydrogenases (11-β-HSDs) are a group of enzymes that play a crucial role in the metabolism of steroid hormones, particularly cortisol and cortisone, which belong to the class of glucocorticoids. These enzymes exist in two isoforms: 11-β-HSD1 and 11-β-HSD2.
1. 11-β-HSD1: This isoform is primarily located within the liver, adipose tissue, and various other peripheral tissues. It functions as a NADPH-dependent reductase, converting inactive cortisone to its active form, cortisol. This enzyme helps regulate glucocorticoid action in peripheral tissues, influencing glucose and lipid metabolism, insulin sensitivity, and inflammation.
2. 11-β-HSD2: This isoform is predominantly found in mineralocorticoid target tissues such as the kidneys, colon, and salivary glands. It functions as a NAD+-dependent dehydrogenase, converting active cortisol to its inactive form, cortisone. By doing so, it protects the mineralocorticoid receptor from being overstimulated by cortisol, ensuring aldosterone specifically binds and activates this receptor to maintain proper electrolyte and fluid balance.
Dysregulation of 11-β-HSDs has been implicated in several disease states, including metabolic syndrome, type 2 diabetes, hypertension, and psychiatric disorders. Therefore, understanding the function and regulation of these enzymes is essential for developing novel therapeutic strategies to treat related conditions.
11-Beta-Hydroxysteroid Dehydrogenase Type 2 (11β-HSD2) is an enzyme that plays a crucial role in the regulation of steroid hormones, particularly cortisol and aldosterone. It is primarily found in tissues such as the kidneys, colon, and salivary glands.
The main function of 11β-HSD2 is to convert active cortisol into inactive cortisone, which helps to prevent excessive mineralocorticoid receptor activation by cortisol. This is important because cortisol can bind to and activate mineralocorticoid receptors, leading to increased sodium reabsorption and potassium excretion in the kidneys, as well as other effects on blood pressure and electrolyte balance.
By converting cortisol to cortisone, 11β-HSD2 helps to protect mineralocorticoid receptors from being overstimulated by cortisol, allowing aldosterone to bind and activate these receptors instead. This is important for maintaining normal blood pressure and electrolyte balance.
Deficiencies or mutations in the 11β-HSD2 enzyme can lead to a condition called apparent mineralocorticoid excess (AME), which is characterized by high blood pressure, low potassium levels, and increased sodium reabsorption in the kidneys. This occurs because cortisol is able to bind to and activate mineralocorticoid receptors in the absence of 11β-HSD2 activity.
Medical Definition:
Mineralocorticoid Receptors (MRs) are a type of nuclear receptor protein that are activated by the binding of mineralocorticoid hormones, such as aldosterone. These receptors are expressed in various tissues and cells, including the kidneys, heart, blood vessels, and brain.
When activated, MRs regulate gene expression related to sodium and potassium homeostasis, water balance, and electrolyte transport. This is primarily achieved through the regulation of ion channels and transporters in the distal nephron of the kidney, leading to increased sodium reabsorption and potassium excretion.
Abnormalities in mineralocorticoid receptor function have been implicated in several diseases, including hypertension, heart failure, and primary aldosteronism.
Hydroxysteroid dehydrogenases (HSDs) are a group of enzymes that play a crucial role in steroid hormone metabolism. They catalyze the oxidation and reduction reactions of hydroxyl groups on the steroid molecule, which can lead to the activation or inactivation of steroid hormones. HSDs are involved in the conversion of various steroids, including sex steroids (e.g., androgens, estrogens) and corticosteroids (e.g., cortisol, cortisone). These enzymes can be found in different tissues throughout the body, and their activity is regulated by various factors, such as hormones, growth factors, and cytokines. Dysregulation of HSDs has been implicated in several diseases, including cancer, diabetes, and cardiovascular disease.
Aldosterone is a hormone produced by the adrenal gland. It plays a key role in regulating sodium and potassium balance and maintaining blood pressure through its effects on the kidneys. Aldosterone promotes the reabsorption of sodium ions and the excretion of potassium ions in the distal tubules and collecting ducts of the nephrons in the kidneys. This increases the osmotic pressure in the blood, which in turn leads to water retention and an increase in blood volume and blood pressure.
Aldosterone is released from the adrenal gland in response to a variety of stimuli, including angiotensin II (a peptide hormone produced as part of the renin-angiotensin-aldosterone system), potassium ions, and adrenocorticotropic hormone (ACTH) from the pituitary gland. The production of aldosterone is regulated by a negative feedback mechanism involving sodium levels in the blood. High sodium levels inhibit the release of aldosterone, while low sodium levels stimulate its release.
In addition to its role in maintaining fluid and electrolyte balance and blood pressure, aldosterone has been implicated in various pathological conditions, including hypertension, heart failure, and primary hyperaldosteronism (a condition characterized by excessive production of aldosterone).
Mineralocorticoid receptor antagonists (MRAs) are a class of medications that block the action of aldosterone, a hormone produced by the adrenal glands. Aldosterone helps regulate sodium and potassium balance and blood pressure by binding to mineralocorticoid receptors in the kidneys, heart, blood vessels, and brain.
When aldosterone binds to these receptors, it promotes sodium retention and potassium excretion, which can lead to an increase in blood volume and blood pressure. MRAs work by blocking the binding of aldosterone to its receptors, thereby preventing these effects.
MRAs are primarily used to treat heart failure, hypertension, and kidney disease. By reducing sodium retention and increasing potassium excretion, MRAs can help lower blood pressure, reduce fluid buildup in the body, and improve heart function. Examples of MRAs include spironolactone and eplerenone.
Cortisone is a type of corticosteroid hormone that is produced naturally in the body by the adrenal gland. It is released in response to stress and helps to regulate metabolism, reduce inflammation, and suppress the immune system. Cortisone can also be synthetically produced and is often used as a medication to treat a variety of conditions such as arthritis, asthma, and skin disorders. It works by mimicking the effects of the natural hormone in the body and reducing inflammation and suppressing the immune system. Cortisone can be administered through various routes, including oral, injectable, topical, and inhalational.
Desoxycorticosterone (also known as desoxycorticosterone or DCZ) is a natural steroid hormone produced by the adrenal gland. It is a weak glucocorticoid and mineralocorticoid, which means it has some effects on blood sugar metabolism and regulates electrolyte and fluid balance in the body.
Desoxycorticosterone is used as a medication in the form of its synthetic acetate ester, desoxycorticosterone acetate (DCA), to treat Addison's disease, a condition in which the adrenal glands do not produce enough steroid hormones. DCA helps to replace the missing mineralocorticoid activity and prevent the symptoms of low blood pressure, dehydration, and electrolyte imbalances associated with Addison's disease.
It is important to note that desoxycorticosterone should only be used under the supervision of a healthcare provider, as it can have significant side effects if not properly monitored.
Hypokalemia is a medical condition characterized by abnormally low potassium levels in the blood, specifically when the concentration falls below 3.5 milliequivalents per liter (mEq/L). Potassium is an essential electrolyte that helps regulate heart function, nerve signals, and muscle contractions.
Hypokalemia can result from various factors, including inadequate potassium intake, increased potassium loss through the urine or gastrointestinal tract, or shifts of potassium between body compartments. Common causes include diuretic use, vomiting, diarrhea, certain medications, kidney diseases, and hormonal imbalances.
Mild hypokalemia may not cause noticeable symptoms but can still affect the proper functioning of muscles and nerves. More severe cases can lead to muscle weakness, fatigue, cramps, paralysis, heart rhythm abnormalities, and in rare instances, respiratory failure or cardiac arrest. Treatment typically involves addressing the underlying cause and replenishing potassium levels through oral or intravenous (IV) supplementation, depending on the severity of the condition.
Apparent mineralocorticoid excess syndrome
Pseudohyperaldosteronism
Corticosteroid 11-beta-dehydrogenase isozyme 2
11β-Hydroxysteroid dehydrogenase type 1
11β-Hydroxysteroid dehydrogenase
Secondary hypertension
Glucocorticoid remediable aldosteronism
Cortisol
List of syndromes
Same
Hypokalemia
AME
Ames
List of MeSH codes (C18)
Hypovolemia
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
List of MeSH codes (C16)
List of diseases (A)
Dydrogesterone
Hyperkalemia
Estrogen insensitivity syndrome
Endocrine system
Combined oral contraceptive pill
Subarachnoid hemorrhage
Diethylstilbestrol
Pharmacology of bicalutamide
Progestogen (medication)
Flutamide
Antiandrogen
Apparent mineralocorticoid excess syndrome - Wikipedia
Clinical, Biochemical, and Genetic Characteristics of 'Nonclassic' Apparent Mineralocorticoid Excess Syndrome - PubMed
Metabolic Alkalosis Treatment & Management: Approach Considerations, Chloride-Responsive Alkalosis, Chloride-Resistant...
Metabolic Alkalosis Treatment & Management: Approach Considerations, Chloride-Responsive Alkalosis, Chloride-Resistant...
Metabolic Alkalosis Treatment & Management: Approach Considerations, Chloride-Responsive Alkalosis, Chloride-Resistant...
Frontiers | Genetic Programming of Hypertension
Limb-Mammary Syndrome - Ontology Browser - Rat Genome Database
restless legs syndrome - Ontology Browser - Rat Genome Database
Hyperaldosteronism - wikidoc
A Review of the Pharmacological Efficacy and Safety of Licorice Root from Corroborative Clinical Trial Findings - PubMed
HuGE Navigator|Genopedia|PHGKB
Hypertension: Practice Essentials, Background, Pathophysiology
Metabolic Alkalosis Treatment & Management: Approach Considerations, Chloride-Responsive Alkalosis, Chloride-Resistant...
MeSH Browser
MeSH Browser
ugt1a10 gene|ugt1a10 gene|C1421323|udp glucuronosyltransferase 1 family, polypeptide a10|gngm
Pesquisa | Portal Regional da BVS
Votre médecin: ERKNet pour les
DeCS
Code System Concept
Rcan1 Mouse Gene Details | regulator of calcineurin 1 | International Mouse Phenotyping Consortium
Endocrine Hypertension | Greenspan's Basic & Clinical Endocrinology, 10e | AccessBiomedical Science | McGraw Hill Medical
NCIt Code NCIt PT Subset PT Subset SY NCIt Definition Subset Definition NCIt Code of First Parent First Parent NCIt Code of...
DeCS 2004 - Novos termos
NEW (2004) MESH HEADINGS WITH SCOPE NOTES (UNIT RECORD FORMAT; 10/2/2003
Glucocorticoids. Medical search
Research Groups
ugt1a10 gene|ugt1a10 gene|C1421323|udp glucuronosyltransferase 1 family, polypeptide a10|gngm
Toronja: MedlinePlus suplementos
Aldosterone19
- Cortisol at high concentrations can cross-react and activate the mineralocorticoid receptor due to the non-selectivity of the receptor, leading to aldosterone-like effects in the kidney. (wikipedia.org)
- Renal losses of hydrogen ions occur whenever the distal delivery of sodium increases in the presence of excess aldosterone, which stimulates the electrogenic epithelial sodium channel (ENaC) in the collecting duct. (medscape.com)
- The key mineralocorticoid is aldosterone. (comprehensivephysiology.com)
- The adverse effects of excess aldosterone are heavily dependent on increased dietary salt intake as has been demonstrated in animal models and in humans. (comprehensivephysiology.com)
- The renin-angiotensin-aldosterone system, the diagnostic and therapeutic approaches to mineralocorticoid hypertension (eg, primary aldosteronism), and less common forms of endocrine hypertension are reviewed in this chapter. (mhmedical.com)
- Mineralocorticoid hypertension is most often caused by autonomous overproduction of aldosterone, but excess of other mineralocorticoid precursors can lead to a similar presentation. (bioscientifica.com)
- This case should alert clinicians to the possibility of a diagnosis of a DOC-producing adrenal tumours in patients with adrenal nodules and apparent mineralocorticoid hypertension in the presence of low or normal levels of aldosterone. (bioscientifica.com)
- However, excess of other mineralocorticoid products, such as DOC, lead to the same syndrome but with normal or low aldosterone levels. (bioscientifica.com)
- The differential diagnosis of resistant hypertension with low renin and low/normal aldosterone includes congenital adrenal hyperplasia, syndrome of apparent mineralocorticoid excess, Cushing's syndrome, Liddle's syndrome and 11-deoxycorticosterone-producing tumours. (bioscientifica.com)
- DOC is one intermediate product in the mineralocorticoid synthesis with weaker activity than aldosterone. (bioscientifica.com)
- Clinical data support the notion that aldosterone can directly alter the function of the immune system and can participate in low-grade inflammation which leads to blood pressure elevation and end organ damage.Objective and hypothesis: To assess in humans, whether aldosterone plasma levels and mineralocorticoid receptor (MR) expression associate. (eurospe.org)
- [ 3 ] The diagnosis of CAH depends on the demonstration of inadequate production of cortisol and/or aldosterone in the presence of accumulation of excess concentrations of precursor hormones. (medscape.com)
- Aldosterone, a steroid hormone with mineralocorticoid activity, is mainly recognized for its action on sodium reabsorption in the distal nephron of the kidney , which is mediated by the epithelial sodium channel (ENaC). (moviecultists.com)
- The kidney is known to be the major target for aldosterone, a mineralocorticoid hormone synthesized in the adrenal cortex that acts on electrolyte transport in the distal nephron. (moviecultists.com)
- Aldosterone excess, whether from genetic causes or primary aldosteronism (hyperplasia or aldosterone-secreting adenomas), is well documented to cause hypertension . (moviecultists.com)
- The causes of hypoaldosteronism include both acquired (secondary mineralocorticoid deficiency) and, less often, inherited disorders (primary mineralocorticoid deficiency), which can affect adrenal aldosterone synthesis or renal (and maybe adrenal) renin release. (studybuff.com)
- Pseudohypoaldosteronism (PHA) comprises a heterogeneous group of disorders of electrolyte metabolism characterized by an apparent state of renal tubular unresponsiveness or resistance to the action of aldosterone. (studybuff.com)
- Primary aldosteronism (also called Conn's syndrome) is a rare condition caused by overproduction of the hormone aldosterone that controls sodium and potassium in the blood. (studybuff.com)
- Addison's disease can be a medical emergency due to deficiency of cortisol, as well as of aldosterone and other mineralocorticoids. (studybuff.com)
Hypertension12
- Apparent mineralocorticoid excess is an autosomal recessive disorder causing hypertension (high blood pressure), hypernatremia (increased blood sodium concentration) and hypokalemia (decreased blood potassium concentration). (wikipedia.org)
- This is what causes the hypokalemia, hypertension, and hypernatremia associated with the syndrome. (wikipedia.org)
- citation needed] DOC excess syndrome is an excessive secretion of 21-hydroxyprogesterone also called 11-Deoxycorticosterone from adrenal glands and may cause mineralocorticoid hypertension. (wikipedia.org)
- Apparent mineralocorticoid excess is a rare form of monogenic hypertension that is transmitted as an autosomal recessive trait. (wikipedia.org)
- mutations in the HSD11B2 gene explain an inherited form of hypertension, the syndrome of apparent mineralocorticoid excess in which cortisol acts as a potent mineralocorticoid. (richardvigilantebooks.com)
- The syndrome of apparent mineralocorticoid excess (AME) is an autosomal recessive disorder characterized by hypertension, hypokalemia, low renin, and hypoaldosteronism. (richardvigilantebooks.com)
- Severe Hypertension in a Girl: Cushing Syndrome or Apparent Mineralocorticoid Excess Syndrome? (eurospe.org)
- Background: Severe deficiency of 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) triggers activation of mineralocorticoid receptor (MR) by cortisol and causing apparent mineralocorticoid excess (AME) syndrome characterized mostly by low-renin arterial hypertension and hypokalemia. (eurospe.org)
- Background: Thyroid dysfunction is a common condition in children and has been associated with metabolic syndrome, hypertension, cardiovascular disease and mortality. (eurospe.org)
- Chronic activation of mineralocorticoid production leads to dysregulation of the cardiovascular system and to hypertension. (comprehensivephysiology.com)
- Complex interaction involving opposition of hypokalemia by drug at mineralocorticoid receptor, and possible reduction in licorice adverse effect of hypertension. (interactionsguide.com)
- 11-Deoxycorticosterone (DOC) excess, which can occur in 11-β hydroxylase or 17-α hydroxylase deficiencies, in DOC-producing adrenocortical tumours or in patients taking 11-β hydroxylase inhibitors, may cause mineralocorticoid hypertension. (bioscientifica.com)
Deficiency4
- This syndrome is characterized by multiple CONGENITAL ABNORMALITIES, growth deficiency, and INTELLECTUAL DISABILITY. (rush.edu)
- Синдроми полігландулярної недостатності Polyglandular deficiency syndromes (PDS) are characterized by sequential or simultaneous deficiencies in the function of several endocrine glands that have a common cause. (msdmanuals.com)
- Because mineralocorticoids stimulate sodium reabsorption and potassium excretion, deficiency results in increased excretion of sodium and decreased excretion of potassium, chiefly in urine but also in sweat, saliva, and the gastrointestinal tract. (msdmanuals.com)
- A result of this deficiency is increased production of corticotropin-releasing hormone and ACTH, and chronically high levels of ACTH which leads to adrenal hyperplasia and production of excess adrenal androgens. (bjuinternational.com)
Cortisol2
- citation needed] Other conditions such as Liddle's Syndrome can mimic the clinical features of AME, so diagnosis can be made by calculating the ratio of free urinary cortisol to free urinary cortisone. (wikipedia.org)
- The adrenal cortex secretes cortico-steroids, which are broadly classified by their function as mineralocorticoids, glucocorticoids (cortisol), and androgens of interest are DHEA and DHEAS. (medium.com)
Receptor1
- Patients with Liddle's syndrome will only respond to a diuretic that binds the ENaC channel, whereas those with AME will respond to a diuretic that binds to ENaC or the mineralcorticoid receptor. (wikipedia.org)
Glucocorticoids2
- Adrenocortical steroidogenic pathways for the production of mineralocorticoids and glucocorticoids. (comprehensivephysiology.com)
- Both mineralocorticoids and glucocorticoids are deficient. (msdmanuals.com)
Sodium2
- The factors affecting cardiac output include sodium intake, renal function, and mineralocorticoids. (medscape.com)
- Administration of sodium bicarbonate in amounts that exceed the capacity of the kidneys to excrete this excess bicarbonate may cause metabolic alkalosis. (medscape.com)
Gitelman Syndrome2
- a good prognosis, but failure to identify and Gitelman syndrome. (who.int)
- Administration of its rarity--to our information this entation ages, Gitelman syndrome is of indomethacin after 6-12 weeks of is the first reported in Iraq--and to found in late childhood or adolescence life 1-5 mg/kg/day is most frequently alert paediatricians in the region to its and has the classic hal mark finding of used and well tolerated [3]. (who.int)
Licorice1
- Special attention needs to be paid to dietary supplements that the patient might be using or has used (e.g. licorice inhibits 11 beta-hydroxysteroid buy Tanespimycin dehydrogenase (type 2), HSD11B2, and might result in the so-called "apparent mineralocorticoid excess syndrome") Functional impairment 17-DMAG (Alvespimycin) HCl is a central to the illness, and the method of determining this should be provided. (plcpathway.com)
Glucocorticoid1
- Treatment is with a glucocorticoid plus, if needed, a mineralocorticoid and, for some female neonates with genital ambiguity, surgical reconstruction. (merckmanuals.com)
Pheochromocytoma1
- Pheochromocytoma and Cushing syndrome are reviewed in detail in Chapters 11 and 9 , respectively. (mhmedical.com)
Bartter6
- Bartter syndrome is a rare metabolic 3rd percentile for age. (who.int)
- Case report the calcium level was in the upper nor- Bartter syndrome, originally described mal range at presentation, which might by Bartter et al. (who.int)
- Birth diagnosis of neonatal Bartter syndrome childhood but the diagnosis can be weight was 3.5 kg. (who.int)
- 3]. In the latter, when no cause can eases such as Bartter syndrome, in which vious siblings have suffered from the be identified (e.g. vomiting, diarrhoea, the majority of patients present with disorder [4]. (who.int)
- With early diagnosis and abuse of diuretics or laxatives), the con- failure to thrive, vomiting and constipa- proper treatment Bartter syndrome has ditions to be differentiated are Bartter tion during the first 2 years of life [6]. (who.int)
- neonatal Bartter syndrome have similar directed to correct dehydration and This syndrome is reported because presenting symptoms but different pres- electrolyte imbalance. (who.int)
Potassium1
- Alternatively, one could differentiate between the two syndromes by administering a potassium-sparing diuretic. (wikipedia.org)
Chronic2
- Chronic fatigue syndrome (CFS) is a debilitating condition that has received increasing attention from researchers in the past decade. (cdc.gov)
- Chronic fatigue syndrome (CFS) is estimated to affect about a million Americans, and to cause considerable disability and economic costs to society (Jason et al. (cdc.gov)
Clinically apparent2
- It occurs in all age groups, about equally in each sex, and tends to become clinically apparent during metabolic stress, infection, or trauma. (msdmanuals.com)
- Edema (other than localized edema as with an allergic reaction) does not become clinically apparent until the interstitial volume has increased by at least 2.5 to 3 liters. (medilib.ir)
Genetic3
- Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity. (medscape.com)
- Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11? (cdc.gov)
- Clinical, Biochemical, and Genetic Characteristics of 'Nonclassic' Apparent Mineralocorticoid Excess Syndrome. (cdc.gov)
Neonates1
- Background: Very preterm neonates are at risk for metabolic syndrome later in life. (eurospe.org)
Severe4
- Junker J, Haverkamp W, Schulze-Bahr E, Eckardt L, Paulus W, Kiefer R. Amiodarone and acetazolamide for the treatment of genetically confirmed severe Andersen syndrome. (medscape.com)
- It quickly became apparent that reducing inpatient mortality rates and early phase prediction of possible deterioration or severe disease course relied on finding more specific biomarkers. (edu.pl)
- This retrospective study assessed initial clinical, laboratory and radiological features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients and explored their impact on mortality and the course of the disease. (edu.pl)
- A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China and caused coronavirus disease (COVID-19), which became a health concern at the end of 2019. (edu.pl)
Therapeutic1
- Introduction: The dichotomous nature of the definition of Metabolic Syndrome (MS) in both children and adults can under-diagnose subjects at risk and prevents adequate follow-up of therapeutic interventions. (eurospe.org)
Cardiovascular disease1
- Mineralocorticoid excess: Closely monitor patients with cardiovascular disease. (nih.gov)
Diagnosis1
- AAEE minimonograph #27: Differential diagnosis of myotonic syndromes. (medscape.com)
Metabolic syndrome2
- Due to the obesity epidemic in paediatric population exists a higher prevalence of nonalcoholic fatty liver disease (NAFLD), a condition associated with insulin resistance and metabolic syndrome. (eurospe.org)
- BACKGROUND: We aimed to study the associations of adipocytokines, endothelial damage markers, and high-sensitivity C-reactive protein (hs-CRP) with metabolic syndrome (MetS) components. (bvsalud.org)
Acute1
- Coronavirus 19 (COVID-19) is well known for causing acute respiratory distress syndrome. (ejcrim.com)
Interstitial1
- In this setting, both the plasma and interstitial volumes are expanded, and deleterious hemodynamic effects from removal of the excess fluid are much less likely. (medilib.ir)
Excessive1
- We describe a case of apparent mineralocorticoid excess due to excessive smoking of liquorice-laced marijuana. (ejcrim.com)
Fluid1
- However, the alteration in capillary hemodynamics results in most of the retained fluid entering the interstitium and eventually becoming apparent as edema. (medilib.ir)
Failure1
- A variety of clinical conditions are associated with the development of edema, including heart failure, cirrhosis, and the nephrotic syndrome ( table 1 ). (medilib.ir)